Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.

Kapitza C, Forst T, Coester HV, Poitiers F, Ruus P, Hincelin-Méry A

Diabetes, obesity & metabolism25 Feb 2013Cited by 151 (Europe PMC)

PMID23368510PMCIDPMC3752965DOI10.1111/dom.12076PepBankPUB-23368510

Summary

AimAssess the pharmacodynamics of lixisenatide once daily (QD) versus liraglutide QD in type 2 diabetes insufficiently controlled on metformin.MethodsIn this 28-day, randomized, open-label, parallel-group, multicentre study (NCT01175473), patients (mean HbA1c 7.3%) received subcutaneous lixisenatide QD (10 µg weeks 1-2, then 20 µg; n = 77) or liraglutide QD (0.6 mg week 1, 1.2 mg week 2, then 1.8 mg; n = 71) 30 min before breakfast. Primary endpoint was change in postprandial plasma glucose (PPG) exposure from baseline to day 28 during a breakfast test meal.ResultsLixisenatide reduced PPG significantly more than liraglutide [mean change in AUC(0:30-4:30h) : -12.6 vs. -4.0 h·mmol/L, respectively; p < 0.0001 (0:30 h = start of meal)]. Change in maximum PPG excursion was -3.9 mmol/l vs. -1.4 mmol/l, respectively (p < 0.0001). More lixisenatide-treated patients achieved 2-h PPG <7.8 mmol/l (69% vs. 29%). Changes in fasting plasma glucose were greater with liraglutide (-0.3 vs. -1.3 mmol/l, p < 0.0001). Lixisenatide provided greater decreases in postprandial glucagon (p < 0.05), insulin (p < 0.0001) and C-peptide (p < 0.0001). Mean HbA1c decreased in both treatment groups (from 7.2% to 6.9% with lixisenatide vs. 7.4% to 6.9% with liraglutide) as did body weight (-1.6 kg vs. -2.4 kg, respectively). Overall incidence of adverse events was lower with lixisenatide (55%) versus liraglutide (65%), with no serious events or hypoglycaemia reported.ConclusionsOnce daily prebreakfast lixisenatide provided a significantly greater reduction in PPG (AUC) during a morning test meal versus prebreakfast liraglutide. Lixisenatide provided significant decreases in postprandial insulin, C-peptide (vs. an increase with liraglutide) and glucagon, and better gastrointestinal tolerability than liraglutide.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study25

25 results from studies that gave the peptide. 25 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes on metformin, postprandial glucose AUC changed by -12.6 with lixisenatide versus -4.0 h·mmol/L with liraglutide (p < 0.0001).
In plain wordsIn patients with diabetes on metformin, lixisenatide reduced post-meal glucose exposure more than liraglutide.
Peptide
Lixisenatide
Outcome
DecreasePostprandial glucose AUC
Study
n = 148
Comparator
Liraglutide once daily, titrated to 1.8 mg
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 µg once daily weeks 1-2, then 20 µg once daily · subcutaneous · 28 daysAs given in this study (human).
Measurements
Mean change in postprandial plasma glucose AUC(0:30-4:30h)
−12.6 h·mmol/L
lixisenatide, baseline to day 28
Mean change in postprandial plasma glucose AUC(0:30-4:30h)
−4 h·mmol/L
liraglutide, baseline to day 28
P value
< 0.0001 unitless
postprandial plasma glucose AUC, lixisenatide vs liraglutide
Source sentences
Summary
Lixisenatide reduced PPG significantly more than liraglutide [mean change in AUC(0:30-4:30h) : -12.6 vs. -4.0 h·mmol/L, respectively; p < 0.0001 (0:30 h = start of meal)].
1 context sentence(design, population, supporting numbers)
Summary · context
In this 28-day, randomized, open-label, parallel-group, multicentre study (NCT01175473), patients (mean HbA1c 7.3%) received subcutaneous lixisenatide QD (10 µg weeks 1-2, then 20 µg; n = 77) or liraglutide QD (0.6 mg week 1, 1.2 mg week 2, then 1.8 mg; n = 71) 30 min before breakfast.
Show in the study text Report a problemFND-2336851014
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, liraglutide reduced postprandial plasma glucose exposure less than lixisenatide.
In plain wordsIn adults with type 2 diabetes, liraglutide lowered blood sugar after a meal, but less than lixisenatide did.
Peptide
Liraglutide
Outcome
DecreaseChange in postprandial plasma glucose AUC(0:30-4:30h)
Study
n = 71
Comparator
Lixisenatide
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 mg week 1, 1.2 mg week 2, then 1.8 mg once daily · subcutaneous · 28 daysAs given in this study (human).
Measurements
Change in PPG AUC(0:30-4:30h)
−4 h·mmol/L
liraglutide
Change in PPG AUC(0:30-4:30h)
−12.6 h·mmol/L
lixisenatide
Source sentences
Summary
Lixisenatide reduced PPG significantly more than liraglutide [mean change in AUC(0:30-4:30h) : -12.6 vs. -4.0 h·mmol/L, respectively; p < 0.0001 (0:30 h = start of meal)].
2 context sentences(design, population, supporting numbers)
Summary · context
Primary endpoint was change in postprandial plasma glucose (PPG) exposure from baseline to day 28 during a breakfast test meal.
Summary · context
In this 28-day, randomized, open-label, parallel-group, multicentre study (NCT01175473), patients (mean HbA1c 7.3%) received subcutaneous lixisenatide QD (10 µg weeks 1-2, then 20 µg; n = 77) or liraglutide QD (0.6 mg week 1, 1.2 mg week 2, then 1.8 mg; n = 71) 30 min before breakfast.
Show in the study text Report a problemFND-2336851001
03HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes on metformin, maximum glucose excursion changed by -3.9 with lixisenatide versus -1.4 mmol/l with liraglutide (p < 0.0001).
In plain wordsIn patients with diabetes on metformin, lixisenatide reduced the maximum post-meal glucose rise more than liraglutide.
Peptide
Lixisenatide
Outcome
DecreaseMaximum postprandial glucose excursion
Study
n = 148
Comparator
Liraglutide once daily, titrated to 1.8 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 µg once daily weeks 1-2, then 20 µg once daily · subcutaneous · 28 daysAs given in this study (human).
Measurements
Change in maximum postprandial plasma glucose excursion
−3.9 mmol/l
lixisenatide
Change in maximum postprandial plasma glucose excursion
−1.4 mmol/l
liraglutide
P value
< 0.0001 unitless
maximum postprandial glucose excursion, lixisenatide vs liraglutide
Source sentences
Summary
Change in maximum PPG excursion was -3.9 mmol/l vs. -1.4 mmol/l, respectively (p < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 28-day, randomized, open-label, parallel-group, multicentre study (NCT01175473), patients (mean HbA1c 7.3%) received subcutaneous lixisenatide QD (10 µg weeks 1-2, then 20 µg; n = 77) or liraglutide QD (0.6 mg week 1, 1.2 mg week 2, then 1.8 mg; n = 71) 30 min before breakfast.
Show in the study text Report a problemFND-2336851015
04HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes on metformin, 69% achieved 2-h glucose <7.8 mmol/l with lixisenatide versus 29% with liraglutide.
In plain wordsIn patients with diabetes on metformin, more reached the post-meal glucose target with lixisenatide than liraglutide.
Peptide
Lixisenatide
Outcome
Increase2-hour postprandial glucose below 7.8 mmol/l
Study
n = 148
Comparator
Liraglutide once daily, titrated to 1.8 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 µg once daily weeks 1-2, then 20 µg once daily · subcutaneous · 28 daysAs given in this study (human).
Measurements
Patients with 2-h postprandial glucose <7.8 mmol/l
69%
lixisenatide
Patients with 2-h postprandial glucose <7.8 mmol/l
29%
liraglutide
Source sentences
Summary
More lixisenatide-treated patients achieved 2-h PPG <7.8 mmol/l (69% vs. 29%).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 28-day, randomized, open-label, parallel-group, multicentre study (NCT01175473), patients (mean HbA1c 7.3%) received subcutaneous lixisenatide QD (10 µg weeks 1-2, then 20 µg; n = 77) or liraglutide QD (0.6 mg week 1, 1.2 mg week 2, then 1.8 mg; n = 71) 30 min before breakfast.
Show in the study text Report a problemFND-2336851016
05HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes on metformin, fasting glucose changed by -0.3 with lixisenatide versus -1.3 mmol/l with liraglutide (p < 0.0001).
In plain wordsIn patients with diabetes on metformin, fasting glucose decreased less with lixisenatide than liraglutide.
Peptide
Lixisenatide
Outcome
IncreaseFasting plasma glucose
Study
n = 148
Comparator
Liraglutide once daily, titrated to 1.8 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 µg once daily weeks 1-2, then 20 µg once daily · subcutaneous · 28 daysAs given in this study (human).
Measurements
Change in fasting plasma glucose
−0.3 mmol/l
lixisenatide
Change in fasting plasma glucose
−1.3 mmol/l
liraglutide
P value
< 0.0001 unitless
fasting plasma glucose change, lixisenatide vs liraglutide
Source sentences
Summary
Changes in fasting plasma glucose were greater with liraglutide (-0.3 vs. -1.3 mmol/l, p < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 28-day, randomized, open-label, parallel-group, multicentre study (NCT01175473), patients (mean HbA1c 7.3%) received subcutaneous lixisenatide QD (10 µg weeks 1-2, then 20 µg; n = 77) or liraglutide QD (0.6 mg week 1, 1.2 mg week 2, then 1.8 mg; n = 71) 30 min before breakfast.
Show in the study text Report a problemFND-2336851017
06HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes on metformin, lixisenatide reduced postprandial glucagon more than liraglutide (p < 0.05).
In plain wordsIn patients with diabetes on metformin, lixisenatide reduced post-meal glucagon more than liraglutide.
Peptide
Lixisenatide
Outcome
DecreasePostprandial glucagon
Study
n = 148
Comparator
Liraglutide once daily, titrated to 1.8 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 µg once daily weeks 1-2, then 20 µg once daily · subcutaneous · 28 daysAs given in this study (human).
Measurements
P value
< 0.05 unitless
postprandial glucagon, lixisenatide vs liraglutide
Source sentences
Summary
Lixisenatide provided greater decreases in postprandial glucagon (p < 0.05), insulin (p < 0.0001) and C-peptide (p < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 28-day, randomized, open-label, parallel-group, multicentre study (NCT01175473), patients (mean HbA1c 7.3%) received subcutaneous lixisenatide QD (10 µg weeks 1-2, then 20 µg; n = 77) or liraglutide QD (0.6 mg week 1, 1.2 mg week 2, then 1.8 mg; n = 71) 30 min before breakfast.
Show in the study text Report a problemFND-2336851018
07HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes on metformin, lixisenatide reduced postprandial insulin more than liraglutide (p < 0.0001).
In plain wordsIn patients with diabetes on metformin, lixisenatide reduced post-meal insulin more than liraglutide.
Peptide
Lixisenatide
Outcome
DecreasePostprandial insulin
Study
n = 148
Comparator
Liraglutide once daily, titrated to 1.8 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 µg once daily weeks 1-2, then 20 µg once daily · subcutaneous · 28 daysAs given in this study (human).
Measurements
P value
< 0.0001 unitless
postprandial insulin, lixisenatide vs liraglutide
Source sentences
Summary
Lixisenatide provided greater decreases in postprandial glucagon (p < 0.05), insulin (p < 0.0001) and C-peptide (p < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 28-day, randomized, open-label, parallel-group, multicentre study (NCT01175473), patients (mean HbA1c 7.3%) received subcutaneous lixisenatide QD (10 µg weeks 1-2, then 20 µg; n = 77) or liraglutide QD (0.6 mg week 1, 1.2 mg week 2, then 1.8 mg; n = 71) 30 min before breakfast.
Show in the study text Report a problemFND-2336851019
08HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes on metformin, lixisenatide reduced postprandial C-peptide more than liraglutide (p < 0.0001).
In plain wordsIn patients with diabetes on metformin, lixisenatide reduced post-meal C-peptide more than liraglutide.
Peptide
Lixisenatide
Outcome
DecreasePostprandial C-peptide
Study
n = 148
Comparator
Liraglutide once daily, titrated to 1.8 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 µg once daily weeks 1-2, then 20 µg once daily · subcutaneous · 28 daysAs given in this study (human).
Measurements
P value
< 0.0001 unitless
postprandial C-peptide, lixisenatide vs liraglutide
Source sentences
Summary
Lixisenatide provided greater decreases in postprandial glucagon (p < 0.05), insulin (p < 0.0001) and C-peptide (p < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 28-day, randomized, open-label, parallel-group, multicentre study (NCT01175473), patients (mean HbA1c 7.3%) received subcutaneous lixisenatide QD (10 µg weeks 1-2, then 20 µg; n = 77) or liraglutide QD (0.6 mg week 1, 1.2 mg week 2, then 1.8 mg; n = 71) 30 min before breakfast.
Show in the study text Report a problemFND-2336851020
09HumanRandomized controlled trialSafety outcome
In patients with type 2 diabetes on metformin, adverse events occurred in 55% with lixisenatide versus 65% with liraglutide.
In plain wordsIn patients with diabetes on metformin, adverse events were less frequent with lixisenatide than liraglutide.
Peptide
Lixisenatide
Outcome
DecreaseOverall adverse event incidence
Study
n = 148
Comparator
Liraglutide once daily, titrated to 1.8 mg
Outcome group
Adverse events · Whole body
Studied dose
10 µg once daily weeks 1-2, then 20 µg once daily · subcutaneous · 28 daysAs given in this study (human).
Measurements
Incidence of adverse events
55%
lixisenatide
Incidence of adverse events
65%
liraglutide
Source sentences
Summary
Overall incidence of adverse events was lower with lixisenatide (55%) versus liraglutide (65%), with no serious events or hypoglycaemia reported.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 28-day, randomized, open-label, parallel-group, multicentre study (NCT01175473), patients (mean HbA1c 7.3%) received subcutaneous lixisenatide QD (10 µg weeks 1-2, then 20 µg; n = 77) or liraglutide QD (0.6 mg week 1, 1.2 mg week 2, then 1.8 mg; n = 71) 30 min before breakfast.
Show in the study text Report a problemFND-2336851023
10HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, liraglutide reduced the maximum postprandial glucose excursion less than lixisenatide.
In plain wordsIn adults with type 2 diabetes, liraglutide lowered the highest blood sugar after a meal, but less than lixisenatide did.
Peptide
Liraglutide
Outcome
DecreaseChange in maximum postprandial glucose excursion
Study
n = 71
Comparator
Lixisenatide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 mg week 1, 1.2 mg week 2, then 1.8 mg once daily · subcutaneous · 28 daysAs given in this study (human).
Measurements
Change in maximum PPG excursion
−1.4 mmol/l
liraglutide
Change in maximum PPG excursion
−3.9 mmol/l
lixisenatide
Source sentences
Summary
Change in maximum PPG excursion was -3.9 mmol/l vs. -1.4 mmol/l, respectively (p < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 28-day, randomized, open-label, parallel-group, multicentre study (NCT01175473), patients (mean HbA1c 7.3%) received subcutaneous lixisenatide QD (10 µg weeks 1-2, then 20 µg; n = 77) or liraglutide QD (0.6 mg week 1, 1.2 mg week 2, then 1.8 mg; n = 71) 30 min before breakfast.
Show in the study text Report a problemFND-2336851002
11HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, 29% of liraglutide patients reached 2-h postprandial glucose below 7.8 mmol/l, against 69% with lixisenatide.
In plain wordsIn adults with type 2 diabetes, fewer people reached the 2-hour after-meal sugar target with liraglutide than with lixisenatide.
Peptide
Liraglutide
Outcome
Not applicablePatients with 2-h postprandial glucose below 7.8 mmol/l
Study
n = 71
Comparator
Lixisenatide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 mg week 1, 1.2 mg week 2, then 1.8 mg once daily · subcutaneous · 28 daysAs given in this study (human).
Measurements
Patients with 2-h PPG <7.8 mmol/l
29%
liraglutide
Patients with 2-h PPG <7.8 mmol/l
69%
lixisenatide
Source sentences
Summary
More lixisenatide-treated patients achieved 2-h PPG <7.8 mmol/l (69% vs. 29%).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 28-day, randomized, open-label, parallel-group, multicentre study (NCT01175473), patients (mean HbA1c 7.3%) received subcutaneous lixisenatide QD (10 µg weeks 1-2, then 20 µg; n = 77) or liraglutide QD (0.6 mg week 1, 1.2 mg week 2, then 1.8 mg; n = 71) 30 min before breakfast.
Show in the study text Report a problemFND-2336851003
12HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, liraglutide reduced fasting plasma glucose more than lixisenatide.
In plain wordsIn adults with type 2 diabetes, liraglutide lowered fasting blood sugar more than lixisenatide did.
Peptide
Liraglutide
Outcome
DecreaseChange in fasting plasma glucose
Study
n = 71
Comparator
Lixisenatide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 mg week 1, 1.2 mg week 2, then 1.8 mg once daily · subcutaneous · 28 daysAs given in this study (human).
Measurements
Change in fasting plasma glucose
−1.3 mmol/l
liraglutide
Change in fasting plasma glucose
−0.3 mmol/l
lixisenatide
Source sentences
Summary
Changes in fasting plasma glucose were greater with liraglutide (-0.3 vs. -1.3 mmol/l, p < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 28-day, randomized, open-label, parallel-group, multicentre study (NCT01175473), patients (mean HbA1c 7.3%) received subcutaneous lixisenatide QD (10 µg weeks 1-2, then 20 µg; n = 77) or liraglutide QD (0.6 mg week 1, 1.2 mg week 2, then 1.8 mg; n = 71) 30 min before breakfast.
Show in the study text Report a problemFND-2336851004
13HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, lixisenatide produced greater decreases in postprandial glucagon than liraglutide.
In plain wordsIn adults with type 2 diabetes, after-meal glucagon fell more with lixisenatide than with liraglutide.
Peptide
Liraglutide
Outcome
Direction not reportedPostprandial glucagon
Study
n = 71
Comparator
Lixisenatide
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
0.6 mg week 1, 1.2 mg week 2, then 1.8 mg once daily · subcutaneous · 28 daysAs given in this study (human).
Source sentences
Summary
Lixisenatide provided greater decreases in postprandial glucagon (p < 0.05), insulin (p < 0.0001) and C-peptide (p < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 28-day, randomized, open-label, parallel-group, multicentre study (NCT01175473), patients (mean HbA1c 7.3%) received subcutaneous lixisenatide QD (10 µg weeks 1-2, then 20 µg; n = 77) or liraglutide QD (0.6 mg week 1, 1.2 mg week 2, then 1.8 mg; n = 71) 30 min before breakfast.
Show in the study text Report a problemFND-2336851005
14HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, lixisenatide produced greater decreases in postprandial insulin than liraglutide.
In plain wordsIn adults with type 2 diabetes, lixisenatide lowered after-meal insulin more than liraglutide did.
Peptide
Liraglutide
Outcome
Direction not reportedPostprandial insulin
Study
n = 71
Comparator
Lixisenatide
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
0.6 mg week 1, 1.2 mg week 2, then 1.8 mg once daily · subcutaneous · 28 daysAs given in this study (human).
Source sentences
Summary
Lixisenatide provided greater decreases in postprandial glucagon (p < 0.05), insulin (p < 0.0001) and C-peptide (p < 0.0001).
Show in the study text Report a problemFND-2336851006
15HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, postprandial C-peptide increased with liraglutide, whereas lixisenatide decreased it.
In plain wordsIn adults with type 2 diabetes, after-meal C-peptide rose with liraglutide but fell with lixisenatide.
Peptide
Liraglutide
Outcome
IncreasePostprandial C-peptide
Study
n = 71
Comparator
Lixisenatide
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
0.6 mg week 1, 1.2 mg week 2, then 1.8 mg once daily · subcutaneous · 28 daysAs given in this study (human).
Source sentences
Summary
decreases in postprandial insulin, C-peptide (vs. an increase with liraglutide)
2 context sentences(design, population, supporting numbers)
Summary · context
Lixisenatide provided greater decreases in postprandial glucagon (p < 0.05), insulin (p < 0.0001) and C-peptide (p < 0.0001).
Summary · context
In this 28-day, randomized, open-label, parallel-group, multicentre study (NCT01175473), patients (mean HbA1c 7.3%) received subcutaneous lixisenatide QD (10 µg weeks 1-2, then 20 µg; n = 77) or liraglutide QD (0.6 mg week 1, 1.2 mg week 2, then 1.8 mg; n = 71) 30 min before breakfast.
Show in the study text Report a problemFND-2336851007
16HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, mean HbA1c decreased with liraglutide, from 7.4% to 6.9%, as it did with lixisenatide.
In plain wordsIn adults with type 2 diabetes, HbA1c fell with liraglutide, and it also fell with lixisenatide.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change
Study
n = 71
Comparator
Lixisenatide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 mg week 1, 1.2 mg week 2, then 1.8 mg once daily · subcutaneous · 28 daysAs given in this study (human).
Measurements
HbA1c baseline
7.4%
liraglutide
HbA1c end
6.9%
liraglutide
Source sentences
Summary
Mean HbA1c decreased in both treatment groups (from 7.2% to 6.9% with lixisenatide vs. 7.4% to 6.9% with liraglutide) as did body weight (-1.6 kg vs. -2.4 kg, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 28-day, randomized, open-label, parallel-group, multicentre study (NCT01175473), patients (mean HbA1c 7.3%) received subcutaneous lixisenatide QD (10 µg weeks 1-2, then 20 µg; n = 77) or liraglutide QD (0.6 mg week 1, 1.2 mg week 2, then 1.8 mg; n = 71) 30 min before breakfast.
Show in the study text Report a problemFND-2336851008
17HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, body weight decreased with liraglutide (-2.4 kg), as it did with lixisenatide (-1.6 kg).
In plain wordsIn adults with type 2 diabetes, body weight fell with liraglutide, and it also fell with lixisenatide.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n = 71
Comparator
Lixisenatide
Outcome group
Body weight · Metabolic and weight
Studied dose
0.6 mg week 1, 1.2 mg week 2, then 1.8 mg once daily · subcutaneous · 28 daysAs given in this study (human).
Measurements
Body weight change
−2.4 kg
liraglutide
Body weight change
−1.6 kg
lixisenatide
Source sentences
Summary
Mean HbA1c decreased in both treatment groups (from 7.2% to 6.9% with lixisenatide vs. 7.4% to 6.9% with liraglutide) as did body weight (-1.6 kg vs. -2.4 kg, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 28-day, randomized, open-label, parallel-group, multicentre study (NCT01175473), patients (mean HbA1c 7.3%) received subcutaneous lixisenatide QD (10 µg weeks 1-2, then 20 µg; n = 77) or liraglutide QD (0.6 mg week 1, 1.2 mg week 2, then 1.8 mg; n = 71) 30 min before breakfast.
Show in the study text Report a problemFND-2336851009
18HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on metformin, 65% of liraglutide patients had adverse events, against 55% with lixisenatide.
In plain wordsIn adults with type 2 diabetes, 65% had side effects with liraglutide and 55% with lixisenatide.
Peptide
Liraglutide
Outcome
Not applicableOverall incidence of adverse events
Study
n = 71
Comparator
Lixisenatide
Outcome group
Adverse events · Whole body
Studied dose
0.6 mg week 1, 1.2 mg week 2, then 1.8 mg once daily · subcutaneous · 28 daysAs given in this study (human).
Measurements
Adverse event incidence
65%
liraglutide
Adverse event incidence
55%
lixisenatide
Source sentences
Summary
Overall incidence of adverse events was lower with lixisenatide (55%) versus liraglutide (65%)
1 context sentence(design, population, supporting numbers)
Summary · context
In this 28-day, randomized, open-label, parallel-group, multicentre study (NCT01175473), patients (mean HbA1c 7.3%) received subcutaneous lixisenatide QD (10 µg weeks 1-2, then 20 µg; n = 77) or liraglutide QD (0.6 mg week 1, 1.2 mg week 2, then 1.8 mg; n = 71) 30 min before breakfast.
Show in the study text Report a problemFND-2336851010
19HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on metformin, no serious adverse events were reported.
In plain wordsIn adults with type 2 diabetes, no serious side effects were reported.
Peptide
Liraglutide
Outcome
No significant changeSerious adverse events
Study
n = 71
Comparator
Lixisenatide
Outcome group
Adverse events · Whole body
Studied dose
0.6 mg week 1, 1.2 mg week 2, then 1.8 mg once daily · subcutaneous · 28 daysAs given in this study (human).
Source sentences
Summary
with no serious events or hypoglycaemia reported.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 28-day, randomized, open-label, parallel-group, multicentre study (NCT01175473), patients (mean HbA1c 7.3%) received subcutaneous lixisenatide QD (10 µg weeks 1-2, then 20 µg; n = 77) or liraglutide QD (0.6 mg week 1, 1.2 mg week 2, then 1.8 mg; n = 71) 30 min before breakfast.
Show in the study text Report a problemFND-2336851011
20HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on metformin, no hypoglycaemia was reported.
In plain wordsIn adults with type 2 diabetes, no low blood sugar events were reported.
Peptide
Liraglutide
Outcome
No significant changeHypoglycaemia
Study
n = 71
Comparator
Lixisenatide
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.6 mg week 1, 1.2 mg week 2, then 1.8 mg once daily · subcutaneous · 28 daysAs given in this study (human).
Source sentences
Summary
with no serious events or hypoglycaemia reported.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 28-day, randomized, open-label, parallel-group, multicentre study (NCT01175473), patients (mean HbA1c 7.3%) received subcutaneous lixisenatide QD (10 µg weeks 1-2, then 20 µg; n = 77) or liraglutide QD (0.6 mg week 1, 1.2 mg week 2, then 1.8 mg; n = 71) 30 min before breakfast.
Show in the study text Report a problemFND-2336851012
21HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on metformin, lixisenatide had better gastrointestinal tolerability than liraglutide.
In plain wordsIn adults with type 2 diabetes, lixisenatide was easier on the stomach and gut than liraglutide.
Peptide
Liraglutide
Outcome
Not applicableGastrointestinal tolerability
Study
n = 71
Comparator
Lixisenatide
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.6 mg week 1, 1.2 mg week 2, then 1.8 mg once daily · subcutaneous · 28 daysAs given in this study (human).
Source sentences
Summary
and better gastrointestinal tolerability than liraglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 28-day, randomized, open-label, parallel-group, multicentre study (NCT01175473), patients (mean HbA1c 7.3%) received subcutaneous lixisenatide QD (10 µg weeks 1-2, then 20 µg; n = 77) or liraglutide QD (0.6 mg week 1, 1.2 mg week 2, then 1.8 mg; n = 71) 30 min before breakfast.
Show in the study text Report a problemFND-2336851013
22HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes on metformin, HbA1c decreased from 7.2% to 6.9% with lixisenatide.
In plain wordsIn patients with diabetes on metformin, HbA1c decreased during lixisenatide treatment compared with baseline.
Peptide
Lixisenatide
Outcome
DecreaseHbA1c change
Study
n = 77
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 µg once daily weeks 1-2, then 20 µg once daily · subcutaneous · 28 daysAs given in this study (human).
Measurements
Mean HbA1c
7.2%
lixisenatide, before treatment
Mean HbA1c
6.9%
lixisenatide, after treatment
Source sentences
Summary
Mean HbA1c decreased in both treatment groups (from 7.2% to 6.9% with lixisenatide vs. 7.4% to 6.9% with liraglutide) as did body weight (-1.6 kg vs. -2.4 kg, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 28-day, randomized, open-label, parallel-group, multicentre study (NCT01175473), patients (mean HbA1c 7.3%) received subcutaneous lixisenatide QD (10 µg weeks 1-2, then 20 µg; n = 77) or liraglutide QD (0.6 mg week 1, 1.2 mg week 2, then 1.8 mg; n = 71) 30 min before breakfast.
Show in the study text Report a problemFND-2336851021
23HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes on metformin, mean body weight changed by -1.6 kg with lixisenatide and by -2.4 kg with liraglutide; no between-group comparison was reported for this outcome.
In plain wordsIn patients with diabetes on metformin, weight went down by 1.6 kg with lixisenatide; weight also went down with liraglutide, by 2.4 kg.
Peptide
Lixisenatide
Outcome
DecreaseBody weight change
Study
n = 77
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
10 µg once daily weeks 1-2, then 20 µg once daily · subcutaneous · 28 daysAs given in this study (human).
Measurements
Body weight change
−1.6 kg
lixisenatide
Body weight change
−2.4 kg
liraglutide
Source sentences
Summary
Mean HbA1c decreased in both treatment groups (from 7.2% to 6.9% with lixisenatide vs. 7.4% to 6.9% with liraglutide) as did body weight (-1.6 kg vs. -2.4 kg, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 28-day, randomized, open-label, parallel-group, multicentre study (NCT01175473), patients (mean HbA1c 7.3%) received subcutaneous lixisenatide QD (10 µg weeks 1-2, then 20 µg; n = 77) or liraglutide QD (0.6 mg week 1, 1.2 mg week 2, then 1.8 mg; n = 71) 30 min before breakfast.
Show in the study text Report a problemFND-2336851022
24HumanNon-randomized trialSafety outcome
In patients with type 2 diabetes on metformin, no serious adverse events were reported with lixisenatide.
In plain wordsIn patients with diabetes on metformin, no serious adverse events were reported during lixisenatide treatment.
Peptide
Lixisenatide
Outcome
Not applicableSerious adverse events
Study
n = 77
Outcome group
Adverse events · Whole body
Studied dose
10 µg once daily weeks 1-2, then 20 µg once daily · subcutaneous · 28 daysAs given in this study (human).
Source sentences
Summary
Overall incidence of adverse events was lower with lixisenatide (55%) versus liraglutide (65%), with no serious events or hypoglycaemia reported.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 28-day, randomized, open-label, parallel-group, multicentre study (NCT01175473), patients (mean HbA1c 7.3%) received subcutaneous lixisenatide QD (10 µg weeks 1-2, then 20 µg; n = 77) or liraglutide QD (0.6 mg week 1, 1.2 mg week 2, then 1.8 mg; n = 71) 30 min before breakfast.
Show in the study text Report a problemFND-2336851024
25HumanNon-randomized trialSafety outcome
In patients with type 2 diabetes on metformin, no hypoglycaemia was reported with lixisenatide.
In plain wordsIn patients with diabetes on metformin, no low blood sugar events were reported during lixisenatide treatment.
Peptide
Lixisenatide
Outcome
Not applicableHypoglycaemia
Study
n = 77
Outcome group
Adverse events · Metabolic and weight
Studied dose
10 µg once daily weeks 1-2, then 20 µg once daily · subcutaneous · 28 daysAs given in this study (human).
Source sentences
Summary
Overall incidence of adverse events was lower with lixisenatide (55%) versus liraglutide (65%), with no serious events or hypoglycaemia reported.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 28-day, randomized, open-label, parallel-group, multicentre study (NCT01175473), patients (mean HbA1c 7.3%) received subcutaneous lixisenatide QD (10 µg weeks 1-2, then 20 µg; n = 77) or liraglutide QD (0.6 mg week 1, 1.2 mg week 2, then 1.8 mg; n = 71) 30 min before breakfast.
Show in the study text Report a problemFND-2336851025

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT01175473

Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes

Sanofin = 148Aug 2010 to Nov 2010

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 28 Nov 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 3
27 Oct 2026, 16:36 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.